Beyond PSA: Managing modern therapeutic options in metastatic castration-resistant prostate cancer

Fatima H. Karzai; Ravi A. Madan; William D. Figg

doi:10.14423/SMJ.0000000000000266

Beyond PSA: Managing modern therapeutic options in metastatic castration-resistant prostate cancer

Fatima H. Karzai, Ravi A. Madan, William D. Figg^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

Prostate cancer is the second leading cause of cancer-related deaths in men in the United States. The role of the prostate-specific antigen in metastatic castrate-resistant prostate cancer has become more defined through the years. This article addresses how prostate-specific antigen criteria alone should not be used as a disease marker to discontinue therapy in metastatic castration-resistant disease.

Original language	English
Pages (from-to)	224-228
Number of pages	5
Journal	Southern Medical Journal
Volume	108
Issue number	4
DOIs	https://doi.org/10.14423/SMJ.0000000000000266
State	Published - 9 Apr 2015
Externally published	Yes

Keywords

PSAWG1
PSAWG2
androgen receptor
metastatic castration resistant
prostate-specific antigen

Access to Document

10.14423/SMJ.0000000000000266

Cite this

@article{c355690ebd754d4a82f3290528dfb207,

title = "Beyond PSA: Managing modern therapeutic options in metastatic castration-resistant prostate cancer",

abstract = "Prostate cancer is the second leading cause of cancer-related deaths in men in the United States. The role of the prostate-specific antigen in metastatic castrate-resistant prostate cancer has become more defined through the years. This article addresses how prostate-specific antigen criteria alone should not be used as a disease marker to discontinue therapy in metastatic castration-resistant disease.",

keywords = "PSAWG1, PSAWG2, androgen receptor, metastatic castration resistant, prostate-specific antigen",

author = "Karzai, {Fatima H.} and Madan, {Ravi A.} and Figg, {William D.}",

note = "Publisher Copyright: Copyright {\textcopyright} 2015 The Southern Medical Association. Unauthorized reproduction of this article is prohibited.",

year = "2015",

month = apr,

day = "9",

doi = "10.14423/SMJ.0000000000000266",

language = "English",

volume = "108",

pages = "224--228",

journal = "Southern Medical Journal",

issn = "0038-4348",

number = "4",

}

TY - JOUR

T1 - Beyond PSA

T2 - Managing modern therapeutic options in metastatic castration-resistant prostate cancer

AU - Karzai, Fatima H.

AU - Madan, Ravi A.

AU - Figg, William D.

PY - 2015/4/9

Y1 - 2015/4/9

N2 - Prostate cancer is the second leading cause of cancer-related deaths in men in the United States. The role of the prostate-specific antigen in metastatic castrate-resistant prostate cancer has become more defined through the years. This article addresses how prostate-specific antigen criteria alone should not be used as a disease marker to discontinue therapy in metastatic castration-resistant disease.

AB - Prostate cancer is the second leading cause of cancer-related deaths in men in the United States. The role of the prostate-specific antigen in metastatic castrate-resistant prostate cancer has become more defined through the years. This article addresses how prostate-specific antigen criteria alone should not be used as a disease marker to discontinue therapy in metastatic castration-resistant disease.

KW - PSAWG1

KW - PSAWG2

KW - androgen receptor

KW - metastatic castration resistant

KW - prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=84926655616&partnerID=8YFLogxK

U2 - 10.14423/SMJ.0000000000000266

DO - 10.14423/SMJ.0000000000000266

M3 - Review article

C2 - 25871992

AN - SCOPUS:84926655616

SN - 0038-4348

VL - 108

SP - 224

EP - 228

JO - Southern Medical Journal

JF - Southern Medical Journal

IS - 4

ER -

Beyond PSA: Managing modern therapeutic options in metastatic castration-resistant prostate cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this